Methotrexate and etanercept-induced primary cutaneous CD4 positive small/medium-sized pleomorphic T-cell lymphoma
An. bras. dermatol
; 91(3): 368-371, graf
Article
in En
| LILACS
| ID: lil-787311
Responsible library:
BR1.1
ABSTRACT
Abstract Immunosuppressive drugs and biological agents may represent a potential risk of lymphoma development in patients with rheumatoid arthritis. But most cases are diffuse, large B-cell lymphomas. Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma, a provisional entity in the 2005 WHO-EORTC classification of cutaneous lymphomas, is only described in a limited number of reports. To our knowledge, our case is a rare instance of primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma, after associated treatment with methotrexate and etanercept, in a patient with moderate rheumatoid arthritis who had undergone an orchidectomy incorrectly.
Key words
Full text:
1
Index:
LILACS
Main subject:
Skin Neoplasms
/
Methotrexate
/
Lymphoma, T-Cell, Cutaneous
/
Etanercept
/
Immunosuppressive Agents
Type of study:
Diagnostic_studies
Limits:
Humans
/
Male
Language:
En
Journal:
An. bras. dermatol
Journal subject:
DERMATOLOGIA
Year:
2016
Type:
Article